Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pan HER2: A Multicenter, Non-interventional, Descriptive Study to Assess Assay Concordance of HER2 IHC Testing in Chinese Pan-tumor Patients

NCT07404202 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07404202
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07404202 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pan HER2: A Multicenter, Non-interventional, Descriptive Study to Assess Assay Concordance of HER2 IHC Testing in Chinese Pan-tumor Patients
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Recruiting
Start date
March 6, 2026
Completion date
December 31, 2026
Enrollment
2,100 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

pan-tumor(nsclc, gyn cancers, btc and uc)